MCID: HPT070
MIFTS: 43

Hepatosplenic T-Cell Lymphoma

Categories: Cancer diseases, Liver diseases, Immune diseases, Blood diseases, Rare diseases

Aliases & Classifications for Hepatosplenic T-Cell Lymphoma

MalaCards integrated aliases for Hepatosplenic T-Cell Lymphoma:

Name: Hepatosplenic T-Cell Lymphoma 55 69

Characteristics:

Orphanet epidemiological data:

55
hepatosplenic t-cell lymphoma
Age of onset: Adolescent,Adult;

Classifications:



External Ids:

Orphanet 55 ORPHA86882
UMLS via Orphanet 70 C1333984
ICD10 via Orphanet 33 C86.1
ICD10 32 C86.1
UMLS 69 C1333984

Summaries for Hepatosplenic T-Cell Lymphoma

MalaCards based summary : Hepatosplenic T-Cell Lymphoma is related to lymphoma and leukemia. An important gene associated with Hepatosplenic T-Cell Lymphoma is SETD2 (SET Domain Containing 2). The drugs Vincristine and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include spleen, t cells and bone.

Related Diseases for Hepatosplenic T-Cell Lymphoma

Diseases related to Hepatosplenic T-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Related Disease Score Top Affiliating Genes
1 lymphoma 10.9
2 leukemia 10.4
3 crohn's disease 10.4
4 inflammatory bowel disease 10.3
5 large granular lymphocyte leukemia 10.2
6 t-cell large granular lymphocyte leukemia 10.2
7 hepatitis 10.1
8 thrombocytopenia 10.1
9 acute leukemia 10.1
10 hematopoietic stem cell transplantation 10.1
11 orbit lymphoma 10.0 GZMB TIA1
12 lichen sclerosus et atrophicus 10.0 GZMB TIA1
13 lymphomatoid granulomatosis 10.0 GZMB TIA1
14 viral esophagitis 10.0 GZMB TIA1
15 subcutaneous panniculitis-like t-cell lymphoma 10.0 GZMB TIA1
16 lymphocytic gastritis 10.0 GZMB TIA1
17 primary cutaneous anaplastic large cell lymphoma 10.0 GZMB TIA1
18 natural killer cell leukemia 10.0 GZMB TIA1
19 composite lymphoma 10.0 GZMB TIA1
20 choriocarcinoma of the testis 10.0 GZMB TIA1
21 lymphomatoid papulosis 10.0 GZMB TIA1
22 giardiasis 9.9 GZMB TIA1
23 peripheral t-cell lymphoma 9.9 GZMB TIA1
24 hemolytic anemia 9.9
25 ring chromosome 7 9.9
26 hepatitis b 9.9
27 systemic lupus erythematosus 9.9
28 schistosoma mansoni infection, susceptibility/ 9.9
29 sinusitis 9.9
30 myelofibrosis 9.9
31 leukemia, acute myeloid 9.9
32 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.9
33 myelodysplastic syndrome 9.9
34 autoimmune lymphoproliferative syndrome, type v 9.9
35 schistosomiasis 9.9
36 membranoproliferative glomerulonephritis 9.9
37 autoimmune hepatitis 9.9
38 purpura 9.9
39 common variable immunodeficiency 9.9
40 progressive multifocal leukoencephalopathy 9.9
41 t-cell leukemia 9.9
42 glomerulonephritis 9.9
43 myeloid leukemia 9.9
44 lupus erythematosus 9.9
45 infiltrating lipoma 9.9 GZMB TIA1
46 necrotizing sialometaplasia 9.9 GZMB TIA1
47 panniculitis 9.9 GZMB TIA1
48 b-cell expansion with nfkb and t-cell anergy 9.8 GZMB TIA1
49 reticulosarcoma 9.8 GZMB TIA1
50 lymphoma, hodgkin, classic 9.6 GZMB TIA1

Graphical network of the top 20 diseases related to Hepatosplenic T-Cell Lymphoma:



Diseases related to Hepatosplenic T-Cell Lymphoma

Symptoms & Phenotypes for Hepatosplenic T-Cell Lymphoma

Drugs & Therapeutics for Hepatosplenic T-Cell Lymphoma

Drugs for Hepatosplenic T-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 147)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vincristine Approved, Investigational Phase 4,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
2
Etoposide Approved Phase 4,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
3
Methotrexate Approved Phase 4,Phase 2 1959-05-2, 59-05-2 126941
4
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
5
Infliximab Approved Phase 4 170277-31-3
6
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 1 53-03-2 5865
7
Doxorubicin Approved, Investigational Phase 4,Phase 1,Phase 2 23214-92-8 31703
8
Ifosfamide Approved Phase 4,Phase 1 3778-73-2 3690
9
Mechlorethamine Approved, Investigational Phase 4,Phase 2,Phase 1 51-75-2 4033
10
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 1 58-05-9 143 6006
11
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 59-30-3 6037
12
Doxil Approved June 1999 Phase 4,Phase 1,Phase 2 31703
13
Pirarubicin Investigational Phase 4 72496-41-4
14 Antirheumatic Agents Phase 4,Phase 1,Phase 2,Early Phase 1
15 Alkylating Agents Phase 4,Phase 2,Phase 1,Early Phase 1
16 glucocorticoids Phase 4,Phase 2,Phase 1
17 Folic Acid Antagonists Phase 4,Phase 2,Phase 1
18 Gastrointestinal Agents Phase 4,Phase 2
19 Topoisomerase Inhibitors Phase 4,Phase 2,Phase 1,Early Phase 1
20 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2
21 Hormone Antagonists Phase 4,Phase 2,Phase 1
22 Dermatologic Agents Phase 4,Phase 2,Phase 1
23 Vitamin B Complex Phase 4,Phase 2,Phase 1
24 Hormones Phase 4,Phase 2,Phase 1
25 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 1
26 Anti-Bacterial Agents Phase 4,Phase 2,Phase 1
27 Etoposide phosphate Phase 4,Phase 2,Phase 1,Early Phase 1
28 Immunosuppressive Agents Phase 4,Phase 2,Phase 1,Early Phase 1
29 Antimetabolites Phase 4,Phase 2,Phase 1
30 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 1
31 Antimetabolites, Antineoplastic Phase 4,Phase 2,Phase 1
32 Antimitotic Agents Phase 4,Phase 2,Phase 1
33 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 1
34 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 1
35 Antineoplastic Agents, Phytogenic Phase 4,Phase 2,Phase 1,Early Phase 1
36 Isophosphamide mustard Phase 4,Phase 1 0
37 Folate Nutraceutical Phase 4,Phase 2,Phase 1
38 Vitamin B9 Nutraceutical Phase 4,Phase 2,Phase 1
39
rituximab Approved Phase 1, Phase 2 174722-31-7 10201696
40
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
41
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492
42
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
43
Iron Approved Phase 2 7439-89-6 23925
44
Gemcitabine Approved Phase 2,Phase 1 95058-81-4 60750
45
Mycophenolic acid Approved Phase 2,Phase 1 24280-93-1 446541
46
Mycophenolate mofetil Approved, Investigational Phase 2,Phase 1 128794-94-5 5281078
47
Dasatinib Approved, Investigational Phase 1, Phase 2 302962-49-8 3062316
48
Fludarabine Approved Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
49
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
50
Vidarabine Approved, Investigational Phase 2,Phase 1 24356-66-9 21704 32326

Interventional clinical trials:

(show top 50) (show all 68)

# Name Status NCT ID Phase Drugs
1 Observational Study on the Occurrence of Hepatosplenic T-cell Lymphoma in Patients of Netherlands Completed NCT00731536 Phase 4
2 A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) Recruiting NCT01804166 Phase 4 Infliximab;Golimumab
3 CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma Active, not recruiting NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
4 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
5 Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma Completed NCT01336933 Phase 2 prednisone;cyclophosphamide;etoposide;vincristine sulfate;pralatrexate
6 Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma Completed NCT01466881 Phase 2 Alisertib
7 Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma Completed NCT00131937 Phase 2 sorafenib tosylate
8 Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma Completed NCT00901147 Phase 2 panobinostat and bortezomib
9 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
10 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
11 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Completed NCT01273766 Phase 2 deferasirox
12 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
13 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
14 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
15 Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone
16 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer Completed NCT00049504 Phase 2 cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
17 Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies Completed NCT00481871 Phase 1, Phase 2 Pralatrexate Injection;Gemcitabine Hydrochloride
18 Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Recruiting NCT03075553 Phase 2
19 Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma Recruiting NCT02561273 Phase 1, Phase 2 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Lenalidomide;Prednisone;Vincristine Sulfate
20 A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) Recruiting NCT02588651 Phase 2 Brentuximab vedotin
21 Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma Recruiting NCT02232516 Phase 2 romidepsin;lenalidomide
22 Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma Recruiting NCT03113500 Phase 2 Brentuximab Vedotin;Cyclophosphamide;Doxorubicin;Etoposide;Prednisone
23 CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma Recruiting NCT02742727 Phase 1, Phase 2
24 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Recruiting NCT01760655 Phase 2 Fludarabine phosphate;Thiotepa;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
25 Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies Recruiting NCT01643603 Phase 1, Phase 2 Dasatinib
26 Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Recruiting NCT01609816 Phase 1, Phase 2 Dasatinib
27 Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Active, not recruiting NCT01261247 Phase 2 panobinostat
28 Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Active, not recruiting NCT01839916 Phase 2
29 Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Active, not recruiting NCT01075321 Phase 1, Phase 2 everolimus;lenalidomide
30 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Active, not recruiting NCT01529827 Phase 2 fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
31 Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma Active, not recruiting NCT00918333 Phase 1, Phase 2 panobinostat;everolimus
32 Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer Active, not recruiting NCT00089011 Phase 2 fludarabine phosphate;mycophenolate mofetil;tacrolimus
33 Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer Active, not recruiting NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
34 Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant Active, not recruiting NCT00078858 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
35 Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies Active, not recruiting NCT00040846 Phase 2 fludarabine phosphate;mycophenolate mofetil;cyclosporine
36 Ipilimumab and Local Radiation Therapy in Treating Patients With Recurrent Melanoma, Non-Hodgkin Lymphoma, Colon, or Rectal Cancer Terminated NCT01769222 Phase 1, Phase 2
37 Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant Terminated NCT01419795 Phase 2 lenalidomide
38 Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies Withdrawn NCT01652014 Phase 2 cyclophosphamide;fludarabine phosphate;mycophenolate mofetil;tacrolimus
39 Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma Completed NCT01129180 Phase 1 azacitidine;bortezomib
40 Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies Completed NCT01658319 Phase 1 fludarabine phosphate;methoxyamine
41 MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma Completed NCT01748721 Phase 1
42 Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers Completed NCT01254578 Phase 1 Lenalidomide
43 Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy Completed NCT00890747 Phase 1 sunitinib malate
44 Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery Completed NCT00608361 Phase 1 Dasatinib
45 Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma Completed NCT00458731 Phase 1 cediranib maleate
46 Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma Completed NCT01273090 Phase 1 imetelstat sodium
47 CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma Recruiting NCT02168140 Phase 1 6,8-bis(benzylthio)octanoic acid;bendamustine hydrochloride
48 Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas Active, not recruiting NCT01445535 Phase 1 EPOCH
49 Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies Active, not recruiting NCT01678443 Phase 1
50 Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma Active, not recruiting NCT01567709 Phase 1 Alisertib;Vorinostat

Search NIH Clinical Center for Hepatosplenic T-Cell Lymphoma

Genetic Tests for Hepatosplenic T-Cell Lymphoma

Anatomical Context for Hepatosplenic T-Cell Lymphoma

MalaCards organs/tissues related to Hepatosplenic T-Cell Lymphoma:

38
Spleen, T Cells, Bone, B Cells, Bone Marrow, Endothelial, Thyroid

Publications for Hepatosplenic T-Cell Lymphoma

Articles related to Hepatosplenic T-Cell Lymphoma:

(show top 50) (show all 107)
# Title Authors Year
1
Loss of CD3 and TCRI^I' expression in a relapsed hepatosplenic T-cell lymphoma. ( 28573906 )
2018
2
Hepatosplenic T-cell Lymphoma: A Review of Clinicopathologic Features, Pathogenesis and Prognostic Factors. ( 29337025 )
2018
3
Leukemic phase of hepatosplenic T-cell lymphoma: A great masquerader of acute leukemia. ( 28937394 )
2017
4
Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor-I+ inhibitor therapy and literature review. ( 28038706 )
2017
5
Distinguishing Between Hepatosplenic T-cell Lymphoma and I^I' T-cell Large Granular Lymphocytic Leukemia: A Clinicopathologic, Immunophenotypic, and Molecular Analysis. ( 27755009 )
2017
6
Hepatosplenic T-cell lymphoma associated with membranoproliferative glomerulonephritis. ( 28351190 )
2017
7
The Genetic Basis of Hepatosplenic T-cell Lymphoma. ( 28122867 )
2017
8
Incidence, clinical findings, and survival of hepatosplenic T-cell lymphoma in the United States. ( 28263402 )
2017
9
Four hepatosplenic T-cell lymphoma cases of Japanese patients. ( 26870659 )
2016
10
Hepatosplenic T Cell Lymphoma in an Immunocompetent Female Diagnosed using Flow Cytometry: A Rare Clinical Entity. ( 27656456 )
2016
11
Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases. ( 26872013 )
2016
12
Two Cases of Hepatosplenic T-Cell Lymphoma in Adolescents Treated for Autoimmune Hepatitis. ( 27516526 )
2016
13
Hepatosplenic T-cell lymphoma with blastoid morphology in a patient with Crohn disease. ( 27811192 )
2016
14
Cutaneous presentation of hepatosplenic T-cell lymphoma-a potential mimicker of primary cutaneous gamma-delta T-cell lymphoma. ( 27562705 )
2016
15
Hepatosplenic T-Cell Lymphoma Mimicking Acute Myeloid Leukemia. ( 26708981 )
2016
16
Hepatosplenic T-cell lymphoma: an acute leukemia presentation. ( 27158719 )
2016
17
Hepatosplenic T-cell lymphoma in a 47-year-old Crohn's disease patient on thiopurine monotherapy. ( 28058028 )
2016
18
Hepatosplenic T-cell lymphoma in a young immunocompetent man. ( 27033291 )
2016
19
Dyspoietic changes associated with hepatosplenic T-cell lymphoma are not a manifestation of a myelodysplastic syndrome: analysis of 25 patients. ( 26997444 )
2016
20
Hepatosplenic T-cell lymphoma with coexistent hepatitis B infection: a rare clinicopathologic entity. ( 26481866 )
2015
21
Gastroenterology: Hepatosplenic T cell lymphoma associated with schistosomiasis. ( 26211690 )
2015
22
Hepatosplenic T-Cell Lymphoma: A Population-Based Study Assessing Incidence and Association With Immune-Mediated Disease. ( 27099586 )
2015
23
Childhood Hepatosplenic T-cell Lymphoma with Skin Involvement. ( 26061932 )
2015
24
Hepatosplenic T-cell lymphoma with aberrant expression of serum I^-HCG: a case report. ( 26108251 )
2015
25
Hepatosplenic T-cell lymphoma mimicking bone marrow metastasis. ( 26788568 )
2015
26
Hepatosplenic T-Cell Lymphoma: A Clinicopathologic Review With an Emphasis on Diagnostic Differentiation From Other T-Cell/Natural Killer-Cell Neoplasms. ( 26317456 )
2015
27
Outcomes of allogeneic stem cell transplantation in hepatosplenic T-cell lymphoma. ( 26047388 )
2015
28
Hepatosplenic T-cell lymphoma. ( 25221804 )
2014
29
Frequent STAT5B mutations in I^I' hepatosplenic T-cell lymphomas. ( 24947020 )
2014
30
De novo CD3 negative hepatosplenic T-cell lymphoma: diagnostic challenges and pitfalls. ( 24978925 )
2014
31
Hepatosplenic T cell lymphoma. ( 25332524 )
2014
32
Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT Lymphoma Working Party. ( 25234166 )
2014
33
Lymphoma with features intermediate between aggressive T-large granular lymphocytic leukemia and hepatosplenic T-cell lymphoma: a diagnostic dilemma? ( 24524924 )
2014
34
Hepatosplenic T-cell lymphoma: A case series. ( 25450840 )
2014
35
Successful treatment with reduced-intensity cord blood transplant in a patient with relapsed refractory hepatosplenic T-cell lymphoma. ( 25065703 )
2014
36
Coexistent hairy cell leukaemia and hepatosplenic T-cell lymphoma: a case report. ( 24621139 )
2014
37
Simultaneous hepatosplenic T-cell lymphoma and myelofibrosis. ( 24761381 )
2014
38
Hepatosplenic T-cell lymphoma, immunosuppressive agents and biologicals: what are the risks? ( 24621284 )
2014
39
Hepatosplenic T-cell lymphoma: a rare cause of hepatosplenomegaly. ( 25012882 )
2014
40
Integrative genomic and transcriptomic analysis identified candidate genes implicated in the pathogenesis of hepatosplenic T-cell lymphoma. ( 25057852 )
2014
41
Hepatosplenic T cell lymphoma: a rare case report. ( 25332523 )
2014
42
Purpura of the face and neck: an atypical clinical presentation revealing a hepatosplenic T cell lymphoma. ( 24707248 )
2014
43
Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience. ( 23107915 )
2013
44
CD4(-)/CD8(-) variant of T-cell large granular lymphocytic leukemia or hepatosplenic T-cell lymphoma: a clinicopathologic dilemma. ( 23800602 )
2013
45
Use of case reports and the Adverse Event Reporting System in systematic reviews: overcoming barriers to assess the link between Crohn's disease medications and hepatosplenic T-cell lymphoma. ( 23826928 )
2013
46
Hepatosplenic T-cell lymphoma. ( 24033076 )
2013
47
Hepatosplenic T-cell lymphoma: is cure possible? ( 23598915 )
2013
48
Histopathological, immunophenotypic and clinical particularities and evolution of a case of hepatosplenic T-cell lymphoma in transformation to leukemia. ( 24399013 )
2013
49
Hepatosplenic T-cell lymphoma appearing in the peripheral blood. ( 24137640 )
2013
50
Successful treatment of hepatosplenic T-cell lymphoma with ESHAP followed by autologous stem cell transplant. ( 23598914 )
2013

Variations for Hepatosplenic T-Cell Lymphoma

Expression for Hepatosplenic T-Cell Lymphoma

LifeMap Discovery
Genes differentially expressed in tissues of Hepatosplenic T-Cell Lymphoma patients vs. healthy controls: 35 (show top 50) (show all 400)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 TMEM178A transmembrane protein 178A Spleen + 9.71 0.000
2 LPAR3 lysophosphatidic acid receptor 3 Spleen + 8.91 0.000
3 SOX2 SRY (sex determining region Y)-box 2 Spleen + 8.60 0.000
4 MLC1 megalencephalic leukoencephalopathy with subcortical cysts 1 Spleen + 7.68 0.001
5 CLEC3B C-type lectin domain family 3, member B Spleen - 7.16 0.001
6 KIR2DS1 killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 1 Spleen + 7.16 0.000
7 HLA-DQA1 major histocompatibility complex, class II, DQ alpha 1 Spleen - 7.01 0.023
8 KIR3DL1 killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 1 Spleen + 6.95 0.000
9 KIR3DS1 killer cell immunoglobulin-like receptor, three domains, short cytoplasmic tail, 1 Spleen + 6.85 0.001
10 ADAMTS17 ADAM metallopeptidase with thrombospondin type 1 motif, 17 Spleen + 6.83 0.000
11 KIR3DL3 killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 3 Spleen + 6.66 0.000
12 KIR2DL3 killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 3 Spleen + 6.63 0.001
13 MARCO macrophage receptor with collagenous structure Spleen + 6.61 0.009
14 KIR2DS3 killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 3 Spleen + 6.34 0.001
15 CXCL13 chemokine (C-X-C motif) ligand 13 Spleen - 6.26 0.004
16 OLFML2A olfactomedin-like 2A Spleen - 6.25 0.015
17 KIR2DL2 killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 2 Spleen + 6.21 0.002
18 KIR2DS2 killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 2 Spleen + 6.14 0.000
19 KIR2DS4 killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 4 Spleen + 6.13 0.001
20 GREB1 growth regulation by estrogen in breast cancer 1 Spleen + 6.09 0.001
21 KIR2DL1 killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 1 Spleen + 6.02 0.002
22 LOC100505501 uncharacterized LOC100505501 Spleen + 5.96 0.000
23 MAATS1 MYCBP-associated, testis expressed 1 Spleen - 5.93 0.000
24 TRGV5 T cell receptor gamma variable 5 Spleen + 5.90 0.000
25 CRHBP corticotropin releasing hormone binding protein Spleen - 5.89 0.000
26 KLRC3 killer cell lectin-like receptor subfamily C, member 3 Spleen + 5.87 0.000
27 SMIM24 small integral membrane protein 24 Spleen + 5.85 0.000
28 CCM2L cerebral cavernous malformation 2-like Spleen - 5.83 0.005
29 RUNDC3B RUN domain containing 3B Spleen + 5.82 0.000
30 HLA-DQB1 major histocompatibility complex, class II, DQ beta 1 Spleen + 5.80 0.000
31 PCDH7 protocadherin 7 Spleen - 5.78 0.010
32 APLNR apelin receptor Spleen - 5.76 0.000
33 KIR2DL5A killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 5A Spleen + 5.73 0.001
34 KIR2DS5 killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 5 Spleen + 5.69 0.001
35 GIPC2 GIPC PDZ domain containing family, member 2 Spleen - 5.69 0.000
36 GTSF1 gametocyte specific factor 1 Spleen + 5.62 0.001
37 GPM6A glycoprotein M6A Spleen - 5.62 0.000
38 IGFBP3 insulin-like growth factor binding protein 3 Spleen - 5.61 0.004
39 BMP7 bone morphogenetic protein 7 Spleen + 5.59 0.000
40 PDE2A phosphodiesterase 2A, cGMP-stimulated Spleen - 5.58 0.002
41 KIF14 kinesin family member 14 Spleen + 5.55 0.000
42 HYAL1 hyaluronoglucosaminidase 1 Spleen - 5.51 0.006
43 GPR82 G protein-coupled receptor 82 Spleen + 5.49 0.000
44 DNASE1L3 deoxyribonuclease I-like 3 Spleen - 5.44 0.003
45 USP44 ubiquitin specific peptidase 44 Spleen + 5.44 0.000
46 CD96 CD96 molecule Spleen + 5.42 0.001
47 AKAP5 A kinase (PRKA) anchor protein 5 Spleen + 5.41 0.000
48 RNASE1 ribonuclease, RNase A family, 1 (pancreatic) Spleen - 5.40 0.008
49 PLVAP plasmalemma vesicle associated protein Spleen - 5.38 0.001
50 NEK2 NIMA-related kinase 2 Spleen + 5.35 0.000
Search GEO for disease gene expression data for Hepatosplenic T-Cell Lymphoma.

Pathways for Hepatosplenic T-Cell Lymphoma

GO Terms for Hepatosplenic T-Cell Lymphoma

Biological processes related to Hepatosplenic T-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 T cell activation GO:0042110 8.8 CD7 DPP4 PIK3CD

Molecular functions related to Hepatosplenic T-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 alpha-tubulin binding GO:0043014 8.62 INO80 SETD2

Sources for Hepatosplenic T-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....